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Aims: Guidelines support routine surveillance testing for rejection for at least 5-years after heart 
transplant (HT). In patients greater than 2-years post-HT, we examined which clinical characteristics 
predict continuation of routine surveillance studies, outcomes following discontinuation of routine 
surveillance, and the cost-effectiveness of different surveillance strategies.  
 
Methods: We retrospectively identified subjects older than 18 who underwent a first HT at our center 
from 2007-2016 and who survived >760 days (n=217) post-HT. The clinical context surrounding all 
endomyocardial biopsies (EMBs) and gene expression profiles (GEPs) was reviewed to determine if 
studies were performed routinely or were triggered by a change in clinical status. Subjects were 
categorized as following a test-based (TB)-surveillance (n=159) or a signs/symptoms (SS)-surveillance 
(n=53) strategy based on treating cardiologist intent to continue routine studies after the second post-
transplant year. A Markov model was constructed to compare two TB-surveillance strategies to a baseline 
strategy of discontinuing routine studies. 
 
Results: 1,020 studies were performed; 835 were routine. Significant rejection was absent in 99.0% of 
routine EMBs and 99.8% of routine GEPs. The treating cardiologist’s practice duration, patient age, and 
immunosuppressive regimen predicted surveillance strategy. There were no differences in outcomes 
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between groups. Routine surveillance EMBs cost more and were marginally less effective than a strategy 
of discontinuing routine studies after 2-years; surveillance GEPs had an incremental cost effectiveness 
ratio of $1.67 million/quality-adjusted life-year. 
 
Conclusions: Acute asymptomatic rejection is rare after the second post-transplant year. Obtaining 
surveillance studies beyond the second post-transplant year is not cost-effective.  
 
Key words: transplantation, cost-effectiveness, gene expression profile, endomyocardial biopsy 
Introduction. 
Routine surveillance testing for rejection is performed frequently in patients after heart transplant 
(HT) to enable identification and treatment of asymptomatic rejection, which is associated with an 
outstanding prognosis when treated early. Left untreated, asymptomatic rejection may progress to 
hemodynamically significant rejection, which carries a much poorer prognosis.(1, 2) Surveillance is 
performed using either endomyocardial biopsies (EMBs) or non-invasive gene expression profiles 
(GEPs).(3) While the risks of complications associated with a routine EMB are low, they may be 
significant and include ventricular perforation, pseudoaneurysm, arrhythmias, and damage to the tricuspid 
valve with the potential for tricuspid insufficiency leading to right heart failure.(4) While GEPs avoid 
upfront risk, positive studies necessitate a confirmatory EMB as the test’s positive predictive value is only 
4.3% in patients greater than 6-months after HT.(5)  
In the modern transplant era, the incidence of acute rejection is low beyond the first post-
transplant year.(4, 6-8) However, guidelines continue to support routine EMBs for 5-years post-HT in 
higher risk patients and beyond 5-years per clinical judgement; GEPs are recommended in low risk 
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patients 6-months to 5-years post-HT (Table 1).(3) These recommendations have led to diverse 
surveillance practices given providers’ concern about the potential consequences of rejection and their 
individual risk aversion. We examined which clinical characteristics impact a patient’s surveillance 
strategy, clinical outcomes following discontinuation of routine surveillance for rejection, and the cost-
effectiveness of different surveillance strategies in patients greater than 2-years after HT at a single center 
with heterogeneous practice patterns.  
 
Methods. 
Patient population and data collection. 
We retrospectively identified subjects age 18 or older who underwent a first HT at the University 
of Michigan from January 2007 until January 2016 and who survived at least 760 days post-HT. Last 
follow-up was April 2018. Information was collected through chart review on patient characteristics and 
treating cardiologist. The study was approved by the University of Michigan Institutional Review Board. 
Informed consent was not required given the retrospective nature of this work. The investigation 
conforms with the principles outlined in the Declaration of Helsinki. 
 
Definitions. 
Rejection was defined according to the 2004 revised International Society of Heart and Lung 
Transplant (ISHLT) criteria.(9) Significant rejection was defined as 2R or 3R acute cellular rejection 
(ACR), antibody-mediated rejection (AMR), or hemodynamically significant biopsy-negative rejection. 
Consistent with guideline recommendations, 1R cellular rejection in the absence of signs or symptoms of 
rejection is not treated at our institution.(3) The clinical context surrounding all EMBs and GEPs was 
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reviewed to determine if they were performed routinely or were triggered by a change in clinical status. 
We evaluated studies after day 760 as we assumed that routine studies scheduled for the end of the second 
year could be delayed by up to 30 days. Studies were considered triggered if they (1) deviated from the 
subject’s previously defined surveillance schedule and a rationale for doing so was provided; (2) were 
performed in follow-up of a positive GEP, as defined by the treating cardiologist; or (3) were performed 
within 360 days of a significant episode of rejection, irrespective of the time of the initial positive biopsy. 
 
Surveillance biopsy protocols. 
At our center, surveillance biopsy practices are determined for each recipient by their transplant 
cardiologist though suggested protocols are available for reference (Table S1). Subjects were categorized 
into two groups based on their stated surveillance strategy at 2-years: “test-based (TB) surveillance” 
versus “signs/symptoms (SS) surveillance.” Subjects following a TB-surveillance strategy underwent 
routine studies to survey for rejection per their treating cardiologist; those following a SS-surveillance 
strategy only underwent testing in the setting of signs or symptoms suggestive of rejection or in follow-up 
of a recent episode of rejection, as defined above. The intended surveillance strategy was determined by 
reviewing provider documentation at the end of year 2 and, if not available, explicitly through ordering 
practices. For example, in the latter case, a provider who orders no surveillance studies for four years’ 
post-HT then orders an EMB can be assumed to be following a SS-surveillance strategy. In 5 instances, 
we were unable to ascertain whether the provider intended to continue routine studies; these subjects were 
excluded from analyses of surveillance strategy. For analysis of covariates predictive of surveillance 
strategy, treating cardiologist was only defined for subjects followed by a single adult cardiologist in the 
third post-transplant year and beyond and when the cardiologist followed at least 3 subjects in this cohort. 





The methods for the cost-effectiveness analysis are described in detail in the supplementary 
methods. In brief, a Markov model was constructed to compare 3 strategies from months 24-60 after 
transplant: (1) a SS-surveillance strategy; (2) routine EMB every 6-months; and (3) routine GEP every 6-
months. In all strategies, patients underwent an EMB for signs or symptoms of rejection. The analysis 
was performed with TreeAge Pro 2019 Software (Williamstown, MA). 
Patients entered the model after 24-months of routine management. The Markov model cycle 
length was 30 days. Patients could enter each cycle well or with signs or symptoms of rejection (Figure 
1).  Patients who entered into the model well could either remain well, die, or undergo routine screening 
with either a GEP or an EMB, as appropriate. Elevated GEP scores led to a follow-up EMB. Patients then 
progressed to ACR, AMR, the well state, or the dead state. Patients who entered into the model with signs 
or symptoms of rejection could either die or undergo an EMB. After an EMB, patients transitioned to 
ACR, AMR, the well state, or the dead state. After AMR or ACR, patients transitioned to alive or dead. 
The model cycled until 60-months post-HT. 
Hospitalization costs for rejection, in 2015 US dollars, were based on the Healthcare Cost and 
Utilization Project,(10) and costs for tests and procedures on the Medicare & Medicaid Services 
Physician fee schedule (Table S6).(11) Medication costs were derived from an internal University of 
Michigan pharmacy database. Patients were assumed to be treated as an inpatient for AMR and 
symptomatic ACR and as an outpatient for asymptomatic ACR.  
The probabilities used in the analysis were derived from the 159 patients (4,645 cycles) following 
a TB-surveillance strategy after the second post-transplant year, as described above (Table S7). To 
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estimate rejection rates with the SS-surveillance strategy, we applied rejection rates from the two TB-
surveillance arms and assumed that all patients with routinely detected rejection would instead present 
with signs or symptoms of hemodynamically significant rejection and then die at the end of the cycle. 
Utilities were based on literature review and, when unavailable, expert opinion (Table S8). In a sensitivity 
analysis, we quadrupled the overall rate of rejection detected by routine studies (Table S7). 
 
Statistical Analysis. 
Data were evaluated for normality and summarized as mean ± standard deviation or median [25th, 
75th percentile]. Patient characteristics by surveillance strategy were compared using the chi-square or 
Fischer’s exact test for categorical variables and the t-test for continuous variables. Univariable logistic 
regression was performed on clinical characteristics to identify those predictive of surveillance strategy; 
stepwise multivariable logistic regression was used to determine independent predictors of surveillance 
strategy. A Cox proportional hazards model was used to compare outcomes by surveillance strategy. 
Linear regression was used to evaluate which clinical characteristics predicted number of studies 
performed after post-transplant year 2. Univariable models identified candidate variables (p<0.15) for the 
final multivariable linear regression model utilizing a stepwise selection process. For all multivariable 
analyses, a p-value < 0.05 was considered significant. All statistical analyses were performed in SAS 




This article is protected by copyright. All rights reserved.
8 
 
Between January 2007 and January 2016, 251 adult subjects underwent a first HT at the 
University of Michigan. Thirty-one (31) subjects died or transferred care to another center prior to day 
760, and 3 were followed by a pediatric cardiologist; 217 subjects were included in the analysis (Table 2). 
Most were male (76%) and white (82%) with a mean age of 51.5 ± 13.0 years at the time of transplant. 
Fifty-six (56) subjects experienced 70 episodes of 2R or 3R cellular rejection in the first two years after 
HT; 60 episodes in 52 subjects in post-transplant year 1 and 10 episodes in 10 subjects in post-transplant 
year 2. One subject had AMR 15-months post-HT. At the end of the second post-transplant year, one-
hundred and thirty-three (133; 61.3%) subjects were on prednisone at a median dose of 2.5 mg [2.5, 5.0]. 
Three-drug and two-drug regimens including a calcineurin inhibitor were used by 44.2% and 35.9% of 
study subjects, respectively. Mean duration of follow-up was 6.3 ± 2.7 years. 
 
Results of routine and triggered studies. 
We evaluated the differential yield of routine and triggered studies. After day 760, 1,020 studies 
were performed in 169 of 217 subjects of which 370 were EMBs and 650 GEPs. A total of 835 (81.9%) 
studies were routine of which 634 (75.9%) were GEPs and 201 (24.1%) EMBs, with the decision to 
pursue routine EMBs versus GEPs driven by perceived patient risk (Table S1). Routine surveillance 
EMBs were negative for significant rejection in 99.0% of cases (Figure 2). One patient, with no prior 
history of rejection, had 2R ACR on a routine surveillance EMB 782 days after HT. That subject had a 
BNP level of 183 pg/mL on the day the study was performed, increased from 116 pg/mL when last 
checked, and a level of 428 pg/mL on the day the biopsy result became available. The second subject, 
who had experienced a previous episode of ACR 128 days after HT, experienced AMR grade 2 on an 
EMB 912 days after HT. Earlier that day, the subject had presented to clinic with signs of heart failure 
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with a BNP of 571 pg/mL, increased from 65 pg/mL when last checked. Thus, these subjects had BNP 
trends and, in one subject, a clinical presentation that may have otherwise triggered an evaluation for 
rejection. While routine BNPs are not required as part of our surveillance protocol (Table S1), they are 
frequently performed at our institution, and a change in BNP > 100 pg/mL has previously been shown at 
our institution to predict increased risk of >2R rejection with high sensitivity and a high positive 
predictive value.(12)  
One-hundred twelve (112, 17.7%) of 634 routine GEPs had scores > 34; 36 GEPs led to a follow-
up EMB. Only 1 EMB 825 days after HT demonstrated 2R ACR, which was treated with prednisone as 
an outpatient given the patient’s lack of symptoms, normal BNP, and unchanged echocardiogram. In two 
instances, one asymptomatic patient received prednisone between his GEP and a grade 0 EMB 854 days 
and 1404 days after transplant. In the first instance, he was presumptively treated with a standard oral 
prednisone burst and taper as he was traveling far from the transplant center. In the second instance, he 
was treated by his primary care physician with 2 days of oral prednisone for coincident gout prior to his 
EMB. Given the low yield of GEPs, these most likely represent false positive test results. While it is 
conceivable that rejection was treated prior to the EMB, this is less likely, especially in the second 
instance in which treatment duration was brief. When considering only routine GEPs obtained within 5 
years of HT, consistent with ISHLT guideline recommendations (Table 1),(3) 73 (16.3%) of 449 GEPs 
had scores ≥ 34, which led to 29 EMBs, only 1 of which demonstrated ACR (3.4% of EMBs; 0.2% of all 
GEPs).   
There were 185 triggered studies of which 169 (91.4%) were EMBs and 16 (8.6%) GEPs (Figure 
2). There was AMR on 24 triggered EMBs from 5 subjects with 22 of 24 episodes occurring in 3 subjects 
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with persistent AMR. Three (3) studies demonstrated 2R cellular rejection. Seven (7) subjects were 
treated for biopsy-negative rejection.  
 
Predictors of Surveillance Strategy. 
 In total, 159 (75%) subjects followed a TB-surveillance strategy and 53 (25%) a SS-surveillance 
strategy (Table 2). Follow-up was nominally but not significantly shorter for the TB-surveillance group 
compared to the SS-surveillance group (5.7 ± 2.5 years versus 6.5 ± 2.7 years; p=0.06). After day 760, 17 
studies were performed in the SS-surveillance group and 965 studies in the TB-surveillance group. A 
multivariable logistic regression model which included treating cardiologist practice duration 
(dichotomized as < 20-years and >20-years based on clustering in practice duration), patient age, and 
immunosuppressive regimen predicted surveillance strategy, accounting for a large amount of the 
variability (c-statistic 0.85). The model was overwhelmingly driven by the treating cardiologist’s practice 
duration (Table 3; Table S2). Subjects were more likely to follow a TB-surveillance strategy if they were 
younger, managed by a cardiologist who had been in practice for < 20-years, or were on a three-drug 
immunosuppressive regimen with a calcineurin inhibitor. In a multivariable Cox proportional hazards 
model adjusting for patient age at the time of transplant, there were no differences in time to death, heart 
failure hospitalization, myocardial infarction/revascularization, or their composite by surveillance strategy 
(Table S3).  
We additionally evaluated the number of studies performed per subject, adjusting for duration of 
follow-up. Treating cardiologists’ practice duration and subjects’ histories of rejection predicted the 
number of studies per subject (Table S4). Across cardiologists, the number of studies after post-transplant 
year 2 ranged from 0.31 studies/patient-year to 2.20 studies/patient-year (Table S5).  





In the 159 subjects following a TB-surveillance strategy, two episodes of rejection were detected 
between years 2 and 5 at a gross cost of $967,014.80 per episode. In our cost effectiveness analysis, 
compared to a baseline strategy of performing studies only for signs or symptoms of rejection, TB-
surveillance EMBs were less effective and cost more; surveillance GEPs had an incremental cost 
effectiveness ratio (ICER) of $1.67 million/quality-adjusted life-year (QALY), grossly in excess of the 
“willingness to pay” threshold of $100,000 per QALY often invoked in the United States to define cost-
effective interventions (Table 4; supplemental results).  In a sensitivity analysis in which the overall rate 
of rejection was quadrupled, both surveillance EMBs and surveillance GEPs were marginally more 
effective than the baseline strategy though substantially more costly (Table S9).  
 
Discussion. 
Current guidelines support routine EMBs for at least 5-years post-HT in higher risk patients and 
routine GEPs 6-months to 5-years post-HT in low risk patients. In light of these permissive guidelines, 
routine surveillance for rejection is often continued beyond the second post-transplant year. At our 
institution, 75% of transplant cardiologists intended to continue routine surveillance studies beyond this 
time point. In the prospective Outcomes Allomap Registry (OAR), of the 933 patients enrolled within the 
first year post-transplant, 20.2% continued routine surveillance GEPs beyond the second post-transplant 
year (personal correspondence Jeffrey Teuteberg). 
This high frequency of testing is continued despite the observed temporal decline in the incidence 
of rejection.(2, 13) In the ISHLT registry, 12.6% of patients transplanted between 2010 and 2016 were 
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treated for rejection between hospital discharge and 1-year post-transplant, an approximately 50% decline 
when compared to 2004-2006.(14) In a second single-center study, only 1.5% of asymptomatic patients 
had rejection detected on a routine EMB between 2000-2011 compared to 6.1% of patients between 1990-
2000.(6) The risk for rejection declines even further with greater time from transplant. In a large 
multicenter registry, there was a 2.4 fold decrease in the risk of rejection when comparing patients 2- 
versus 5-years post-transplant.(2) We similarly found a low risk for acute rejection on routine studies. 
Two (2) of 201 (1.0%) routine EMBs demonstrated acute rejection; 449 routine GEPs between 2 and 5-
years post-transplant lead to 29 EMBs (6.5%), only 1 of which demonstrated ACR (3.4% of EMBs; 0.2% 
of all GEPs). Thus, when performed consistent with guideline recommendations, even a positive test 
results in a very low likelihood of rejection in this low risk population.  
This high frequency of testing exposes patients to potentially unnecessary risks and comes at a 
high cost to both the patient and society. Consistent with Bayes theorem, a positive test result in a low-
risk patient will only marginally raise the post-test probability for disease, leading to a large number of 
false positive test results. If a sequential testing strategy of GEPs followed by EMBs when positive is 
employed, unnecessary downstream testing will result. In our cost effectiveness analysis, surveillance 
EMBs were associated with lower quality of life adjusted survival than the baseline strategy yet cost 
significantly more. Similarly, GEPs resulted in a marginal improvement in quality of life adjusted 
survival (+0.01) but cost significantly more than the baseline strategy with an ICER of $1.67 
million/QALY. We obtained these results despite a very conservative assumption that patients who 
experienced a rejection event in the SS-surveillance arm would present with signs or symptoms of 
hemodynamically significant rejection and then die at the end of the cycle. In reality, a very high 
percentage of late asymptomatic rejection resolves spontaneously without any augmentation in 
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immunosuppression (15), making routine EMBs and GEPs even less effective than our analysis would 
suggest.  
Differences in surveillance strategies were primarily driven by providers’ practice duration and 
likely reflect their varying levels of discomfort with low though ever present risk. Our mental calculus, 
however, differentially weights clinical outcomes and may fail to account for the risks and costs 
associated with unnecessary testing. At our center, we found less experienced physicians more likely to 
continue routine surveillance studies. Whether provider surveillance practices differ at our center by 
perception of risk or acceptance of risk cannot be determined from this study. While different centers will 
vary at what threshold they are willing to accept missed episodes of rejection, we believe these data 
justify revising our institutional post-transplant protocols. Thus, we are now requiring physicians to 
provide justification for routinely ordered surveillance studies after post-transplant year 2. 
Our study should be interpreted in the context of several limitations. First, we evaluated patients 
from a single-center with a relatively small number of African American patients (2); thus our lessons 
learned may not be applicable to all transplant centers or all populations. Secondly, studies were classified 
as routine or triggered based on retrospective chart review. By classifying all studies within one year of a 
positive EMB as triggered, we artificially decreased the yield of routine studies, potentially impacting the 
results of our cost-effectiveness analysis. Our low incidence of rejection, however, is consistent with real 
world data from the OAR.(8) Next, we classified patients as following a TB-surveillance versus a SS-
surveillance strategy based on review of clinical documentation. While treating cardiologist practice 
duration was a strong predictor of surveillance strategy, we cannot exclude the possibility that 
unmeasured covariates influenced provider practice pattern. Finally, for our cost-effectiveness analysis, 
we did not explicitly account for the false negative rate of GEPs nor for the potential complications of 
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EMBs. The latter, however, would lower the utility and increase the cost of surveillance EMBs, which 
were already the least effective and most costly strategy. Additionally, our results are consistent with a 
prior cost-effectiveness analysis modeling EMB surveillance strategies in post-transplant years 2 and 
3.(16) 
In conclusion, acute asymptomatic rejection is exceedingly rare after the second post-transplant 
year. GEPs obtained beyond this time are highly cost ineffective, and EMBs come at a high cost without 
any gain in quality adjusted survival. Both come at a cost to the patient and society. Our analyses support 
discontinuation of routine surveillance studies after two years for the majority of HT recipients.  
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Figure 1: Markov model. Patients move between health states on the basis of transition probabilities 
assuming 30-day cycles. Patients can enter the model in the well state or with signs or symptoms of 
rejection. During each cycle, patients can either (1) remain well; (2) experience asymptomatic rejection, if 
following a pathway of routine GEPs or EMBs; (3) experience symptomatic acute rejection; or (4) die. 
Patients with rejection detected within 90 days of a prior rejection episode were assumed to enter the 
model with signs or symptoms of rejection. Key: ACR = acute cellular rejection; AMR = antibody 
mediated rejection; EMB = endomyocardial biopsy; GEP = gene expression profile; S/Sx = signs and 
symptoms. 
 
Figure 2: Results of (a) routine and (b) triggered endomyocardial biopsies. A total of 370 
endomyocardial biopsies were performed after post-transplant day 760, 201 of which were routine. Key: 
AMR = antibody mediated rejection; * = grade unspecified.




Statement Class LOE 
“The standard of care for adult HT recipients is to perform periodic EMB during the first 6 
to 12 post-operative months for surveillance of HT rejection. 
IIa C 
“After the first post-operative year, EMB surveillance for an extended period of time (eg, 
every 4 – 6 months) is recommended in HT recipients at higher risk for late acute rejection, 
to reduce the risk for rejection with hemodynamic compromise, and to reduce the risk of 
death in African-American recipients.” 
IIa C 
“Gene Expression Profiling (Allomap) can be used to rule out the presence of ACR of 
grade 2R or greater in appropriate low-risk patients, between 6 months and 5 years after 
HT.” 
IIa B 
Table 1: Select International Society of Heart and Lung Transplantation recommendations for 














n (%) Mean (SD) n (%) Mean (SD) n (%) Mean (SD) 
Demographics 
Patient age at transplant, years  51.5 (13.0)  54.6 (10.0)  50.6 (13.7) 0.02 
Female gender 52 (24.0)  12 (22.6)  38 (23.9)  0.85 
White 178 (82.0)  47 (88.7)  128 (80.5)  0.17 
Transplant Characteristics 
Indication, Ischemic CMP 71 (32.7)  16 (30.2)  55 (34.6)  0.56 
Donor age  33.5 (10.2)  31.5 (11.8)  33.9 (12.1) 0.20 
Episodes 2R or 3R cellular rejection, year 1 52 (24.0)   0.3 (0.5)  0.3 (0.5) 0.88 
Episodes 2R or 3R cellular rejection, year 2 10 (4.6)   0.02 (0.1)  0.06 (0.2) 0.15 
Biopsy-negative rejection, years 1 and 2 5 (2.3)  2 (3.8)  3 (1.9)  0.60 
Antibody-mediated rejection, years 1 and 2 1 (0.5)  0 (0.0)  1 (0.6)  1.00 
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Immunosuppression at 2 years 
Tacrolimus 203 (93.6)  51 (96.2)  150 (94.3)  0.73 
Mycophenolate Mofetil 144 (66.4)  33 (62.3)  108 (57.9)  0.45 
Prednisone 133 (61.3)  27 (50.9)  103 (64.8)  0.07 
Proliferation signal inhibitor 28 (12.9)  6 (11.3)  22 (13.8)  0.64 
Immunosuppression group 
    Group 1 
    Group 2 
    Group 3 




















Comorbid Conditions at time of transplant 
BMI, kg/m2  27.1 (4.6)  26.8 (4.0)  27.2 (4.7) 0.59 
Diabetes mellitus 81 (37.3)  22 (41.5)  56 (35.2)  0.41 
Hypertension 132 (60.8)  31 (58.5)  96 (60.4)  0.81 
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Table 2: Baseline characteristics by surveillance strategy. Counts and percentages are presented for categorical variables. Mean values with 
standard deviations are presented for continuous variables. Only patient age at transplant differed significantly between the two groups. For 
immunosuppression group, group 1 (a 3 drug regimen including a CNI + two of the following: MMF, AZA, PSI, or prednisone), group 2 (a 2 
drug regimen including a CNI + either MMF, AZA or PSI), group 3 (a 2 drug regimen containing CNI + prednisone). Key: AZA = azathioprine; 
BMI = body mass index; CNI = calcineurin inhibitor; CKD = chronic kidney disease; CMP = cardiomyopathy; eGFR = estimated glomerular 
filtration rate; MMF = mycophenolate mofetil; PSI = proliferation signal inhibitor; SD = standard deviation; SS-surveillance = signs/symptoms; 
TB-surveillance = test-based. * 5 subjects could not be categorized as following a TB-surveillance versus a SS-surveillance strategy. 
CKD (eGFR < 60 ml/min/1.73 m2) 87 (40.1)  20 (37.7)  66 (41.5)  0.63 




Odds Ratio (95% CI) χ2 P-value 
Reduction in 
-2 LogL 
Patient age at transplant, years 0.960 (0.928 – 0.993) 5.605 0.018 5.080 
Treating cardiologist practice duration (ref = < 20 
years) 
0.013 (0.002-0.102) 17.199 0.013 52.428 
Immunosuppression group (ref = group 1) 
     Group 2 
     Group 3 
 
0.265 (0.108 – 0.647) 








Table 3: Multivariable logistic regression of clinical variables predicting likelihood of following a TB-surveillance strategy after post-
transplant year 2. Stepwise multivariable logistic regression was used to determine independent predictors of surveillance strategy with exit and 
entry criteria of p <0.05. Reduction in -2 log likelihood was used to select variables for the final model. Subjects whose transplant cardiologist had 
been in practice for < 20 years, were younger, or who were on a 3-drug immunosuppressive regimen with a calcineurin inhibitor were more likely 
to follow a TB-surveillance strategy. For immunosuppression group, group 1 (a 3 drug regimen including a CNI + two of the following: MMF, 
AZA, PSI, or prednisone), group 2 (a 2 drug regimen including a CNI + either MMF, AZA or PSI), group 3 (a 2 drug regimen containing CNI + 
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prednisone). Key: AZA = azathioprine; CNI = calcineurin inhibitor; CI = confidence intervals; LogL = log likelihood; MMF = mycophenolate 
mofetil; PSI = proliferation signal inhibitor; TB = test-based.
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Table 4: Routine EMBs and GEPs are not cost-effective. All displayed columns are in reference to a 
baseline strategy of performing studies only for signs or symptoms of rejection. Compared to the baseline 
strategy, surveillance EMBs were less effective and cost more; surveillance GEPs were marginally more 
effective though cost significantly more. Key: EMB = endomyocardial biopsy; GEP = gene expression 
profile; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.  
*The negative value reflects that EMBs were less effective and cost more than the baseline strategy. 
 
 Incremental Cost ($) Effectiveness (QALY) ICER ($/QALY) 
Baseline  28.76  
Surveillance EMB $18,783.07 28.76 -2,568,087.01* 
Surveillance GEP $16,900.34 28.77 1,668,196.90 
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